Presentation: A 57-year-old woman with clinical stage IVB NSCLC and high Programmed Cell Death ligand 1 (PD-L1) expression of 95% received first-line pembrolizumab monotherapy. After only
phosphorylation, an increase in Reactive Oxygen Species (ROS) production, and the activation of programmed cell death pathways as mitochondrial dysfunction contributes to dopaminergic neuron death. Further modifications…
mounting antitumor immunity thereby improving cancer survival. Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and cytotoxic lymphocyte T associated protein 4 (CTLA-4) boost antitumor
pyroptosis;” OR “necroptosis;” OR “PANoptosis;” OR “PANoptosome;” OR “reprogramming somatic cells;” OR “programmed cell death;” OR “regulated cell death” OR “messenger RNA”. Results: All selected manuscripts were…
Immune checkpoint inhibitors (ICIs) targeting PD-1 (programmed cell death-1) and CTLA-4 (cytotoxic T-lymphocyte antigen-4) have revolutionized cancer immunotherapy, providing durable responses in various cancers…
treat multiple cancers one of which is triple-negative breast cancer positive for Programmed Cell Death Ligand 1 (PD-L1) protein. Multiple immune-related Adverse Drug Reactions (irADRs) have been
RIP1) has emerged as a key molecular switch in inducing necroptosis, an alternative programmed cell death mode that can overcome apoptosis resistance in cancer therapy. Therefore, discovering a substance that
Cytokine-induced apoptosis inhibitor 1 is a protein involved in controlling apoptosis and programmed cell death. The role of cytokine-induced apoptosis inhibitor 1 against lipopolysaccharide-induced myocardial damage…
microRNA-761, and explore the molecular mechanisms governing the growth and programmed cell death in ovarian cancer cells. To identify the targeting association between long noncoding RNA lysyl oxidase-like
genesis and metastasis of malignant cells. Pyroptosis is a newly defined type of programmed cell death reported to have a dual effect on the development of carcinomas and had been
seemingly disparate, share underlying cellular and molecular mechanisms, including aberrant cell proliferation and programmed cell death. This convergence provides a unique opportunity for medication repurposing, where…
Pembrolizumab is a humanized monoclonal antibody targeting the anti-Programmed Cell Death 1 (PD-1) receptor expressed on the surface of cytotoxic T lymphocytes. Currently the introduction of immunotherapy
Introduction: Caspase a family of cysteine protease plays an important role in programmed cell death. Caspase-3 and Caspase-8 are key regulators of apoptosis. Caspase-8 plays principal role
affects all age group and occurs mainly in women. Pyroptosis is a novel programmed cell death featured with a distinct morphology associated with cell bursting and release of proinflammatory cytokines
Pembrolizumab is a Programmed Cell Death protein-1 (PD-1) inhibitor which leads to increased T-cell activity which in turn increases anti-tumor immune response. Although immune-related Adverse
host from getting rid of cancer cells. Drugs that target immune checkpoints, particularly programmed cell death protein 1, have revolutionized the standard treatment plan for Non-Small Cell Lung Cancer
Apoptosis is a programmed cell death mechanism that plays a critical role in normal development, homeostasis, and the immune response. It involves a series of tightly regulated cellular events that
power of the immune system to combat cancer. These agents, such as Programmed Cell death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA-4) inhibitors, work
indicating AN involvement of MMPs in cell migration, signaling, differentiation, cell survival or programmed cell death, ontogenesis and inflammation. ADAMs even have the capability to degrade and transform parts
properties through the regulation of the immune system and a specific type of programmed cell death known as pyroptosis. The final immunological effects are significantly influenced by the phases
treatment of Non-Small Cell Lung Cancer (NSCLC). Although monoclonal antibodies against programmed cell death-1 (PD-1) and PD ligand 1 (PD-L1) are commonly employed in clinical practice
barricade of resistant designated spots Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) and Programmed cell Death 1 (PD1)/PD1 ligand 1 (PD-L1) have been displayed to reestablish antitumor invulnerability
need conjointly shown the potential to interfere with some essential cellular processes, e.g., programmed cell death/apoptosis, drug resistance, DNA damage, polymer replication, or immune reactions. These medications…
first agnostic FDA approval in solid tumors. While monotherapy with anti-programmed cell death protein-1 agents achieves objective response rates (ORR) of around 30% and 1-year overall survival